Journal
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Volume 19, Issue 7, Pages 1281-1283Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1111/IGC.0b013e3181a38e2f
Keywords
Paclitaxel; Hypersensitivity reaction; Abraxane; Chemotherapy
Categories
Ask authors/readers for more resources
Background: Paclitaxel is used in the treatment of most gynecologic malignancies. It is solubilized in Cremophor EL, a polyoxyethylated castor oil agent responsible for the high rate of paclitaxel-associated hypersensitivity reactions. Abraxane, a newer, Cremophor-free form of albumin bound paclitaxel has demonstrated an activity and an improved toxicity profile in breast and lung cancers. Case Reports: Five patients with gynecologic cancers (2 ovarian, 2 endometrial, and I cervical malignancy) received Abraxane after having a hypersensitivity reaction to paclitaxel. All five patients tolerated Abraxane well, experiencing no reactions or major side effects to the drug. Discussion: Abraxane is well tolerated in women with gynecologic cancer who have experienced a paclitaxel-associated hypersensitivity reaction. Further studies are ongoing to determine the clinical activity of Abraxane in the treatment of these malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available